Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
October 28 2020 - 07:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the company will present five abstracts and one Distinguished
Industry Oral Abstract at the upcoming Annual Scientific Meeting of
the American College of Allergy, Asthma & Immunology (ACAAI)
November 13-15, which is being conducted as a virtual meeting.
- Berotralstat Reduces Attacks in
Patients with Hereditary Angioedema (HAE): APeX-2 Trial 48 Week
Results; Distinguished Industry Oral Abstract, Session A, Friday,
November 13, 4:30-5:30 p.m. CT
- Berotralstat Improves
Patient-Reported Quality of Life Through 48 Weeks in the Phase 3
APeX-2 Trial; Poster #154
- Berotralstat Positively Impacts Patient-Reported Satisfaction:
Results from the Phase 3 APeX-2 trial; Poster #158
- Patient Perspectives on the
Treatment Burden of Injectable Medication Administration for
Hereditary Angioedema; Poster #160
- Prophylactic Treatment Burden:
Assessment by Caregivers of Patients with Hereditary Angioedema;
Poster #161
- Understanding Differences in
Perceptions of Hereditary Angioedema Treatment Burden May Improve
Patient-Physician Treatment Care Dialogue; Poster #162
All e-posters are expected to be available
online November 13 at 9:30 a.m. CT at
epostersonline.com/acaai2020.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. BioCryst has several
ongoing development programs including ORLADEYO™ (berotralstat), an
oral treatment for hereditary angioedema, BCX9930, an oral Factor D
inhibitor for the treatment of complement-mediated diseases,
galidesivir, a potential treatment for COVID-19, Marburg virus
disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCryst’s actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: the ongoing COVID-19 pandemic, which
could create challenges in all aspects of BioCryst’s business,
including without limitation delays, stoppages, difficulties and
increased expenses with respect to BioCryst’s and its partners’
development, regulatory processes and supply chains, negatively
impact BioCryst’s ability to access the capital or credit markets
to finance its operations, or have the effect of heightening many
of the risks described below or in the documents BioCryst files
periodically with the Securities and Exchange Commission;
developing and commercializing ORLADEYO (berotralstat) or any HAE
product candidate may take longer or may be more expensive than
planned; BioCryst may not be able to enroll the required number of
subjects in planned clinical trials of product candidates; BioCryst
may not advance human clinical trials with product candidates as
expected; the FDA, EMA, PMDA or other applicable regulatory agency
may require additional studies beyond the studies planned for
product candidates, may not provide regulatory clearances which may
result in delay of planned clinical trials, may impose certain
restrictions, warnings, or other requirements on product
candidates, may impose a clinical hold with respect to such product
candidates, or may withhold market approval for product candidates;
product candidates, if approved, may not achieve market acceptance;
BioCryst’s ability to successfully commercialize its product
candidates, manage its growth, and compete effectively; risks
related to the international expansion of BioCryst’s business; and
actual financial results may not be consistent with expectations,
including that 2020 operating expenses and cash usage may not be
within management's expected ranges. Please refer to the documents
BioCryst files periodically with the Securities and Exchange
Commission, specifically BioCryst’s most recent Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on
Form 8-K, all of which identify important factors that could cause
the actual results to differ materially from those contained in
BioCryst’s forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2023 to Mar 2024